Navigation Links
Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
Date:2/15/2012

MINNEAPOLIS, Feb. 15, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the first enrollment of patients in the CONFIDeNT clinical study in the United Kingdom.

This large multi-center, placebo-controlled study will enroll over 200 patients in up to 20 centers across the UK. Using Uroplasty's minimally-invasive Urgent® PC Neuromodulation System, the study will compare percutaneous tibial nerve stimulation (PTNS) treatments to a sham device for patients suffering from fecal incontinence. Outside of the U.S., Urgent PC has a CE Mark for treating fecal incontinence. This is one of several studies currently being conducted throughout Europe to demonstrate the effectiveness of Urgent PC for treating this debilitating and often under-treated, under-reported condition.

"This new physician-initiated study in the UK is indicative of the interest in using Urgent PC to treat fecal incontinence," said David B. Kaysen, President and CEO of Uroplasty, Inc. "The interest in PTNS treatments from internationally known researchers emphasizes the on-going need for effective therapies to treat this very difficult and challenging condition. For many patients, effective treatment for this oftentimes socially isolating condition may well transform their lives."

The Chief Investigator of the CONFIDeNT study in the UK is Prof. C.H. Knowles, BChir, PhD, FRCS (Gen Surg), Professor of Surgical Research and Hon. Consultant, Colorectal Surgeon, Academic Surgical Unit, Centre for Digestive Diseases, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London. Prof. Knowles stated, "The CONFIDeNT study is a major effort to fully understand how PTNS using Urgent PC, a new and unique technology, can be used to treat patients suffering from this debilitating disease of fecal incontinence.  In addition to Uroplasty's support, we appreciate the grant support of the NHS and National Institute for Health Research (Health Technology Assessment programme) in the UK along with the clinicians associated with Enteric's clinical network."

In the UK, the National Institute of Health estimated in 2007 that 6% of the population under 40 years of age experienced a problem with fecal incontinence either daily or weekly. The rate was 15% in women and 6% to 10% in men over 40 living in the community (noninstitutionalized).  In the U.S., a 2009 study estimated that 5% to 10% of the population experienced fecal incontinence, equating to approximately 15 to 30 million individuals affected in the US.

"Uroplasty is committed to actively work with the key researchers involved in Urgent PC research projects across Europe.  It is premature to discuss the time frames for the completion of these studies because patient enrollment rates are difficult to predict.  We may present additional information as study milestones are achieved," Mr. Kaysen concluded.

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Reports Third Quarter of Fiscal 2012 Financial Results
2. Uroplasty to Issue Third Quarter 2012 Financial Results on January 26, 2012
3. Uroplasty to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference
4. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
5. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
6. Uroplasty to Issue Second Quarter 2012 Financial Results on October 27, 2011
7. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
8. Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
9. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
10. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
11. Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... May 2, 2016 Kalorama Information noted the ... Records) market in a recent white paper.  The healthcare ... physician usage, a growing market are among the top ... Kalorama,s report EMR 2016: The Market for ... seventh complete study of the EMR industry, and the ...
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 03, 2016 , ... The new web-based solution HIPAA ... practices, to better grasp and implement HIPAA’s privacy, security, and data breach requirements. ... well-defined, expert-created path to compliance. HIPAA Institute has positioned itself to be an ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK ... sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over the ... works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Beryl Institute announces ... (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices ... (non-US) based authors, the third volume of PXJ continues to expand PXJ's reach ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Civilian Corps of the ... the civilian nurses that care for its uniformed service members, the retired service members, ... 1974 designating May 6th through May 12th National Nurses Week. It acknowledges the hard ...
(Date:5/2/2016)... WACO, Texas (PRWEB) , ... May 02, 2016 , ... ... Corporation will offer an incentive to people who share their fitness journey on ... footwear and premium first aid products, will award a $100 product voucher each week ...
Breaking Medicine News(10 mins):